Rani Therapeutics
RANI
RANI
31 hedge funds and large institutions have $12.8M invested in Rani Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
9% less funds holding
Funds holding: 34 → 31 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less call options, than puts
Call options by funds: $6K | Put options by funds: $12K
Holders
31
Holding in Top 10
2
Calls
$6K
Puts
$12K
Top Buyers
| 1 | +$5.56M | |
| 2 | +$292K | |
| 3 | +$152K | |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$54K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.5K |
Top Sellers
| 1 | -$80.7K | |
| 2 | -$39K | |
| 3 | -$33.9K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$27.5K |
| 5 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$25.9K |